Home › Companies › Apogee Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Apogee Therapeutics, Inc.’s Form 8-K, filed 2026-06-12 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2024-2025 2025-2026
Explore Apogee Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Apogee Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-12 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Mark C. McKenna | 53,689,547 | -- | -- | 1,515,704 | 1,795,532 | Majority: yes |
| Elect Director: Jennifer Fox | 52,895,552 | -- | -- | 2,309,699 | 1,795,532 | Majority: yes |
| Elect Director: William (BJ) Jones, Jr. | 44,964,804 | -- | -- | 10,240,447 | 1,795,532 | Majority: yes |
| Proposal 2: Ratification of Independent Auditor Appointment The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 was ratified as follows: | 56,960,778 | 1,361 | 38,644 | -- | -- | Majority: yes |
| Proposal 3: Approval on a Non-Binding, Advisory Basis of the Compensation of our Named Executive Officers The compensation of our named executive officers as disclosed in the Proxy Statement was approved on a non-binding, advisory basis as follows: | 54,324,725 | 633,959 | 246,567 | -- | 1,795,532 | Majority: yes |
Source: Apogee Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-12 — read the filing on EDGAR.
Each item below shows how the 257 asset managers that disclosed a Apogee Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 9 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Apogee Therapeutics, Inc.’s own tally for this item (“Proposal 3: Approval on a Non-Binding, Advisory Basis of the Compensation of our Named Executive Officers The compensation of our named executive officers as disclosed in the Proxy Statement was approved on a non-binding”): 54,324,725 for, 633,959 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 74,882,396 outstanding shares: 73% for, 0.9% against (73% of the company cast a for/against vote).
The 256 asset managers below cast 99% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 18,557,605 | 0 | 0 | 0 | For |
| Fidelity | 15,720,881 | 0 | 0 | 0 | For |
| Vanguard | 5,664,476 | 0 | 0 | 0 | For |
| Wellington | 3,616,416 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 2,782,097 | 0 | 0 | 0 | For |
| BlackRock | 2,487,046 | 0 | 0 | 0 | For |
| Janus Henderson | 2,385,756 | 0 | 0 | 0 | For |
| Venrock Adviser, LLC | 1,750,000 | 0 | 0 | 0 | For |
| Jackson National | 1,439,376 | 0 | 0 | 0 | For |
| State Street | 1,216,545 | 8,225 | 0 | 0 | For |
| AllianceBernstein | 1,202,151 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,195,247 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1,152,577 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 1,019,976 | 0 | 0 | 0 | For |
| Charles Schwab | 849,537 | 0 | 0 | 0 | For |
| Federated Hermes | 805,154 | 0 | 0 | 0 | For |
| Voya | 782,438 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 715,020 | 0 | 0 | 0 | For |
| Capital Group | 0 | 697,348 | 0 | 0 | Against |
| Vestal Point Capital, LP | 668,829 | 0 | 0 | 0 | For |
| Remedium Capital Partners, LLC | 583,591 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 568,792 | 0 | 0 | 0 | For |
| Loomis Sayles | 510,520 | 28,853 | 0 | 0 | For |
| First Light Asset Management, LLC | 537,675 | 0 | 0 | 0 | For |
| JPMorgan | 491,100 | 0 | 0 | 0 | For |
Showing the 25 largest of 256 asset managers. See all 256 in the interactive database.
Combines 6 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Apogee Therapeutics, Inc.’s own tally for this item (“Elect Director: Jennifer Fox”): 52,895,552 for, 2,309,699 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 74,882,396 outstanding shares: 71% for, 3% withheld (74% of the company cast a for/withheld vote).
The 84 asset managers below cast 100% of the shares they voted on this item FOR (30,033,523 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 7,760,790 | 0 | 0 | 0 | For |
| Fidelity | 6,673,905 | 0 | 0 | 0 | For |
| Vanguard | 5,230,990 | 0 | 2,316 | 0 | For |
| Jackson National | 1,439,376 | 0 | 0 | 0 | For |
| BlackRock | 1,155,224 | 0 | 0 | 0 | For |
| State Street | 681,648 | 0 | 0 | 0 | For |
| Remedium Capital Partners, LLC | 583,591 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 568,792 | 0 | 0 | 0 | For |
| JPMorgan | 491,100 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 422,457 | 0 | Abstain |
| Voya | 391,219 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 380,003 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 379,608 | 0 | 0 | 0 | For |
| Federated Hermes | 365,125 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 362,287 | 0 | 0 | 0 | For |
| Capital Group | 348,674 | 0 | 0 | 0 | For |
| AllianceBernstein | 312,167 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 267,924 | 0 | 0 | 0 | For |
| Prudential/PGIM | 245,742 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 216,119 | 0 | 0 | 0 | For |
| Hartford | 212,162 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 207,913 | 0 | 0 | 0 | For |
| John Hancock | 201,321 | 0 | 0 | 0 | For |
| Loomis Sayles | 0 | 0 | 197,794 | 0 | Abstain |
| Equitable | 174,600 | 0 | 0 | 0 | For |
Showing the 25 largest of 84 asset managers. See all 84 in the interactive database.
Combines 7 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Apogee Therapeutics, Inc.’s own tally for this item (“Elect Director: Mark C. McKenna”): 53,689,547 for, 1,515,704 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 74,882,396 outstanding shares: 72% for, 2% withheld (74% of the company cast a for/withheld vote).
The 84 asset managers below cast 100% of the shares they voted on this item FOR (30,087,310 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 7,760,790 | 0 | 0 | 0 | For |
| Fidelity | 6,673,905 | 0 | 0 | 0 | For |
| Vanguard | 5,230,995 | 0 | 2,311 | 0 | For |
| Jackson National | 1,439,376 | 0 | 0 | 0 | For |
| BlackRock | 1,155,224 | 0 | 0 | 0 | For |
| State Street | 2,196 | 0 | 679,452 | 0 | Abstain |
| Remedium Capital Partners, LLC | 583,591 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 568,792 | 0 | 0 | 0 | For |
| JPMorgan | 491,100 | 0 | 0 | 0 | For |
| Charles Schwab | 422,457 | 0 | 0 | 0 | For |
| Voya | 391,219 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 378,903 | 0 | 1,100 | 0 | For |
| JANUS INVESTMENT FUND | 379,608 | 0 | 0 | 0 | For |
| Federated Hermes | 365,125 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 362,287 | 0 | 0 | 0 | For |
| Capital Group | 348,674 | 0 | 0 | 0 | For |
| AllianceBernstein | 312,167 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 267,924 | 0 | 0 | 0 | For |
| Prudential/PGIM | 245,742 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 216,119 | 0 | 0 | 0 | For |
| Hartford | 212,162 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 207,913 | 0 | 0 | 0 | For |
| John Hancock | 201,321 | 0 | 0 | 0 | For |
| Loomis Sayles | 197,794 | 0 | 0 | 0 | For |
| Equitable | 174,600 | 0 | 0 | 0 | For |
Showing the 25 largest of 84 asset managers. See all 84 in the interactive database.
Combines 6 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
Apogee Therapeutics, Inc.’s own tally for this item (“Elect Director: William (BJ) Jones, Jr.”): 44,964,804 for, 10,240,447 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 74,882,396 outstanding shares: 60% for, 14% withheld (74% of the company cast a for/withheld vote).
The 84 asset managers below cast 100% of the shares they voted on this item FOR (26,603,379 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 7,760,790 | 0 | 0 | 0 | For |
| Fidelity | 6,656,623 | 0 | 17,282 | 0 | For |
| Vanguard | 5,233,291 | 0 | 15 | 0 | For |
| Jackson National | 1,391,936 | 0 | 47,440 | 0 | For |
| BlackRock | 289,309 | 0 | 865,915 | 0 | Abstain |
| State Street | 1,387 | 0 | 680,261 | 0 | Abstain |
| Remedium Capital Partners, LLC | 583,591 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 557,423 | 0 | 11,369 | 0 | For |
| JPMorgan | 491,100 | 0 | 0 | 0 | For |
| Charles Schwab | 422,457 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 391,219 | 0 | Abstain |
| PENN SERIES FUNDS INC | 378,903 | 0 | 1,100 | 0 | For |
| JANUS INVESTMENT FUND | 379,608 | 0 | 0 | 0 | For |
| Federated Hermes | 365,125 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 67,914 | 0 | 294,373 | 0 | Abstain |
| Capital Group | 348,674 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 312,167 | 0 | Abstain |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 267,924 | 0 | Abstain |
| Prudential/PGIM | 243,487 | 0 | 2,255 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 216,119 | 0 | Abstain |
| Hartford | 212,162 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 207,913 | 0 | Abstain |
| John Hancock | 190,379 | 0 | 10,942 | 0 | For |
| Loomis Sayles | 197,794 | 0 | 0 | 0 | For |
| Equitable | 8,636 | 0 | 165,964 | 0 | Abstain |
Showing the 25 largest of 84 asset managers. See all 84 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Apogee Therapeutics, Inc.’s own tally for this item (“Proposal 2: Ratification of Independent Auditor Appointment The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 was ratified as follow”): 56,960,778 for, 1,361 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 74,882,396 outstanding shares: 76% for, 0.1% against (76% of the company cast a for/against vote).
The 84 asset managers below cast 100% of the shares they voted on this item FOR (30,815,390 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 7,760,790 | 0 | 0 | 0 | For |
| Fidelity | 6,673,905 | 0 | 0 | 0 | For |
| Vanguard | 5,233,306 | 0 | 0 | 0 | For |
| Jackson National | 1,439,376 | 0 | 0 | 0 | For |
| BlackRock | 1,155,224 | 0 | 0 | 0 | For |
| State Street | 681,648 | 0 | 0 | 0 | For |
| Remedium Capital Partners, LLC | 583,591 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 568,792 | 0 | 0 | 0 | For |
| JPMorgan | 491,100 | 0 | 0 | 0 | For |
| Charles Schwab | 422,457 | 0 | 0 | 0 | For |
| Voya | 391,219 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 380,003 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 379,608 | 0 | 0 | 0 | For |
| Federated Hermes | 365,125 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 362,287 | 0 | 0 | 0 | For |
| Capital Group | 348,674 | 0 | 0 | 0 | For |
| AllianceBernstein | 312,167 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 267,924 | 0 | 0 | 0 | For |
| Prudential/PGIM | 245,742 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 216,119 | 0 | 0 | 0 | For |
| Hartford | 212,162 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 207,913 | 0 | 0 | 0 | For |
| John Hancock | 201,321 | 0 | 0 | 0 | For |
| Loomis Sayles | 197,794 | 0 | 0 | 0 | For |
| Equitable | 174,600 | 0 | 0 | 0 | For |
Showing the 25 largest of 84 asset managers. See all 84 in the interactive database.
Ranked by the number of Apogee Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 74,882,396 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | T. Rowe Price | 24.78% |
| 2 | Fidelity | 20.99% |
| 3 | Vanguard | 7.56% |
| 4 | Wellington | 4.83% |
| 5 | RTW INVESTMENTS, LP | 3.72% |
| 6 | BlackRock | 3.32% |
| 7 | Janus Henderson | 3.19% |
| 8 | Venrock Adviser, LLC | 2.34% |
| 9 | Jackson National | 1.92% |
| 10 | State Street | 1.64% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 12.37% | 13F |
| Wellington Management | 5.84% | 13F |
| BlackRock | 5.46% | 13F |
| Vanguard Group | 3.82% | 13F |
| RTW Investments, LP | 3.62% | 13G |
| State Street | 2.89% | 13F |
| Geode Capital | 1.63% | 13F |
| T. Rowe Price | 1.53% | 13F |
| JPMorgan Chase | 1.48% | 13F |
| Morgan Stanley | 1.19% | 13F |
Percentages above are of 74,882,396 shares outstanding, as reported by Apogee Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Apogee Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Apogee Therapeutics, Inc.'s shareholder meeting held 2026-06-09, in the 2025-2026 proxy season, 257 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,762 separate fund positions. On the most widely held item on that ballot — Approval, on a non-binding advisory basis, of the compensation of our named executive officers… — FOR was 99% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Apogee Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-12.
Apogee Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).